Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31565546 | 0.92 | GPR119 (0.46) | GPR119 | |
| SCHEMBL14662691 | 0.88 | GPR119 (0.41) | GPR119HPGDUSP2SMN1; SMN2RECQL | |
| SCHEMBL1475643 | 0.88 | GPR119 (0.51) | GPR119HPGDUSP2SMN1; SMN2 | |
| SCHEMBL57106 | 0.86 | GPR119 (0.53) | GPR119HPGDUSP2SMN1; SMN2RECQL | |
| SCHEMBL31565445 | 0.85 | HPGD (0.41) | GPR119HPGDEPHX1 | |
| SCHEMBL31496083 | 0.83 | GPR119 (0.42) | GPR119HPGDUSP2SMN1; SMN2RECQL | |
| SCHEMBL20077137 | 0.83 | GPR119 (0.48) | GPR119HPGDUSP2SMN1; SMN2RECQL | |
| SCHEMBL484279 | 0.83 | GPR119 (0.53) | GPR119 | |
| SCHEMBL485056 | 0.83 | GPR119 (0.50) | GPR119HPGDUSP2SMN1; SMN2RECQL | |
| SCHEMBL9994892 | 0.83 | GPR119 (0.44) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136578-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2024073475-A9 | CEREBLON LIGANDS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025081092-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025021182-A1 | CYP11A1 INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2025-01-30 | — | — | WO | disclosed |
| WO-2024227104-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BRAF VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024073475-A1 | CEREBLON LIGANDS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024073475-A1 | CEREBLON LIGANDS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-10894775-B2 | Piperidine derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2021-01-19 | — | — | US | disclosed |
| EP-3525790-A2 | PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | Merck Sharp & Dohme Corp. (US) | 2019-08-21 | — | — | EP | disclosed |
| WO-2018071315-A2 | PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |
| WO-2018068296-A1 | PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| EP-2411381-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| WO-2010108651-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | GPR119 206/4885HPGD 386/4885USP2 4864/4885 |
| US-20250136578-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | AR, SHBG, FSHR | GPR119 245/4885HPGD 1132/4885USP2 2530/4885 |
| US-10894775-B2 | Piperidine derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, ADRB1 | GPR119 7/4885HPGD 2120/4885USP2 3324/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | GPR119 206/4885HPGD 386/4885USP2 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.